Proteostasis Therapeutics, Inc. (PTI) financial statements (2021 and earlier)

Company profile

Business Address 80 GUEST STREET
BOSTON, MA 02135
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:701187586
Cash and cash equivalents25293019
Short-term investments44904567
Other undisclosed cash, cash equivalents, and short-term investments000(0)
Restricted cash and investments  0 
Receivables   1
Prepaid expense0000
Other undisclosed current assets1214
Total current assets:711217690
Noncurrent Assets
Operating lease, right-of-use asset13
Property, plant and equipment01171
Restricted cash and investments1120
Other noncurrent assets  00
Other undisclosed noncurrent assets 14  
Total noncurrent assets:1415181
TOTAL ASSETS:851369491
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9886
Accounts payable2222
Accrued liabilities7664
Debt1   
Deferred revenue and credits12
Other liabilities  1 
Other undisclosed current liabilities 1  
Total current liabilities:109109
Noncurrent Liabilities
Long-term debt and lease obligation12   
Operating lease, liability12
Liabilities, other than long-term debt00151
Deferred revenue and credits 1
Other liabilities  15 
Derivative instruments and hedges, liabilities0000
Other undisclosed noncurrent liabilities 13  
Total noncurrent liabilities:1213151
Total liabilities:22222610
Stockholders' equity
Stockholders' equity attributable to parent621146981
Common stock0000
Additional paid in capital399392286239
Accumulated other comprehensive income (loss)00(0)(0)
Accumulated deficit(337)(278)(217)(157)
Total stockholders' equity:621146981
TOTAL LIABILITIES AND EQUITY:851369491

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:5358
Operating expenses(66)(66)(65)(46)
Operating loss:(61)(63)(60)(37)
Nonoperating income2110
Investment income, nonoperating1110
Other nonoperating income (expense)10(0)(0)
Net loss attributable to parent:(59)(62)(59)(37)
Preferred stock dividends and other adjustments   (1)
Net loss available to common stockholders, diluted:(59)(62)(59)(39)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(59)(62)(59)(37)
Comprehensive loss:(59)(62)(59)(37)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent000(0)
Comprehensive loss, net of tax, attributable to parent:(59)(62)(59)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: